Access the full text.
Sign up today, get DeepDyve free for 14 days.
Rudolf Schosser, B. Keller-Stanislawski, C. Nübling, J. Löwer (2001)
Causality assessment of suspected virustransmission by human plasma productsTransfusion, 41
I. Schmidt, Johannes Blümel, H. Seitz, H. Willkommen, Johannes Löwer (2001)
Parvovirus B19 DNA in plasma pools and plasma derivativesVox Sanguinis, 81
A. Servant, S. Laperche, F. Lallemand, V. Marinho, G. Maur, J. Meritet, A. Garbarg‐Chenon (2002)
Genetic Diversity within Human Erythroviruses: Identification of Three GenotypesJournal of Virology, 76
S. Dorsch, B. Kaufmann, U. Schaible, E. Prohaska, H. Wolf, S. Modrow (2001)
The VP1-unique region of parvovirus B19: amino acid variability and antigenic stability.The Journal of general virology, 82 Pt 1
L. Jarvis (2002)
Response 12Vox Sanguinis, 82
J. Blümel, I. Schmidt, W. Effenberger, H. Seitz, H. Willkommen, H. Brackmann, J. Löwer, A. Eis-Hübinger (2002)
Parvovirus B19 transmission by heat‐treated clotting factor concentratesTransfusion, 42
J. Clarke (1907)
MedicineBristol Medico-Chirurgical Journal (1883), 25
J. Coste, H. Reesink, C. Engelfriet, S. Laperche, S. Brown, M. Busch, H. Cuijpers, R. Elgin, B. Ekermo, J. Epstein, O. Flesland, H. Heier, G. Henn, J. Hernandez, I. Hewlett, C. Hyland, A. Keller, T. Krusius, S. Levičnik‐Stezina, G. Levy, C. Lin, A. Margaritis, L. Muylle, C. Niederhauser, S. Pastila, J. Pillonel, J. Pineau, C. Poel, C. Politis, W. Roth, S. Sauleda, C. Seed, D. Sondag‐Thull, S. Stramer, M. Strong, E. Vamvakas, C. Velati, M. Vesga, A. Zanetti (2005)
Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003.Vox sanguinis, 88 4
E. Tabor, M. Yu, I. Hewlett, J. Epstein (2000)
Summary of a workshop on the implementation of NAT to screen donors of blood and plasma for virusesTransfusion, 40
T. Yee, B. Cohen, K. Pasi, C. Lee (1996)
Transmission of symptomatic parvovirus B19 infection by clotting factor concentrateBritish Journal of Haematology, 93
A. Azzi, S. Ciappi, K. Zakvrzewska, M. Morfini, G. Mariani, P. Mannucci (1992)
Human parvovirus B19 infection in hemophiliacs first infused with two high‐purity, virally attenuated factor Vlll concentratesAmerican Journal of Hematology, 39
T. Burnouf, M. Radosevich (2003)
Nanofiltration of plasma‐derived biopharmaceutical productsHaemophilia, 9
J. Blümel, I. Schmidt, H. Willkommen, J. Löwer (2002)
Inactivation of parvovirus B19 during pasteurization of human serum albuminTransfusion, 42
K. Brown, N. Young, B. Alving, L. Barbosa (2001)
Parvovirus B19: implications for transfusion medicine. Summary of a workshopTransfusion, 41
(2000)
Parvovirus B 19 : implications for
A. Eis-Hübinger, U. Sasowski, H. Brackmann (1999)
Parvovirus B19 DNA Contamination in Coagulation Factor VIII ProductsThrombosis and Haemostasis, 81
R. Shade, M. Blundell, S. Cotmore, P. Tattersall, C. Astell (1986)
Nucleotide sequence and genome organization of human parvovirus B19 isolated from the serum of a child during aplastic crisisJournal of Virology, 58
(2002)
Response 5: International Forum
MMWR Morb Mortal Wkly Rep, 51
N. Luban (1994)
Human parvoviruses: implications for transfusion medicineTransfusion, 34
Young Young, Brown Brown (2004)
Mechanisms of disease: parvovirus B19N Engl J Med, 350
H. Matsui, M. Sugimoto, S. Tsuji, M. Shima, J. Giddings, A. Yoshioka (1999)
Transient hypoplastic anemia caused by primary human parvovirus B19 infection in a previously untreated patient with hemophilia transfused with a plasma-derived, monoclonal antibody-purified factor VIII concentrate.Journal of pediatric hematology/oncology, 21 1
(2000)
Presence of human parvovirus B19 DNA in factor VIII concentrates: effects of viral clearance and product purification procedures
J. Saldanha, P. Minor (1996)
Detection of human parvovirus B19 DNA in plasma pools and blood products derived from these pools: implications for efficiency and consistency of removal of B19 DNA during manufactureBritish Journal of Haematology, 93
M. Blundell, C. Beard, C. Astell (1987)
In vitro identification of a B19 parvovirus promoter.Virology, 157 2
A. Azzi, A. Azzi, Massirno Morfini, Massirno Morfini, P. Mannucci, P. Mannucci (1999)
The transfusion-associated transmission of parvovirus B19.Transfusion medicine reviews, 13 3
B. Cohen, M. Buckley (1988)
The prevalence of antibody to human parvovirus B19 in England and Wales.Journal of medical microbiology, 25 2
Claudia Aberham, Claudia Pendl, Patricia Gross, Gerold Zerlauth, M. Gessner (2001)
A quantitative, internally controlled real-time PCR Assay for the detection of parvovirus B19 DNA.Journal of virological methods, 92 2
(2003)
Blood safety monitoring among persons with bleeding disorders--United States, May 1998-June 2002.MMWR. Morbidity and mortality weekly report, 51 51-52
Hewlett Hewlett, Yu Yu, Epstein Epstein (2002)
Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology. The International ForumVox Sang, 82
T. Weimer, S. Streichert, C. Watson, A. Gröner (2001)
High‐titer screening PCR: a successful strategy for reducing the parvovirus B19 load in plasma pools for fractionationTransfusion, 41
J. Aubin, C. Defer, M. Vidaud, M. Montreuil, B. Flan (2000)
Large–Scale Screening for Human Parvovirus B19 DNA by PCR: Application to the Quality Control of Plasma for FractionationVox Sanguinis, 78
Blood Products Advisory Committee. Nucleic acid testing of blood donors for human parvovirus B19
Günter Siegl, P. Cassinotti (1998)
Presence and significance of parvovirus B19 in blood and blood products.Biologicals : journal of the International Association of Biological Standardization, 26 2
Larry Anderson, C. Tsou, Robert Parker, Terence Chorba, H. Wulff, P. Tattersall, P. Mortimer (1986)
Detection of antibodies and antigens of human parvovirus B19 by enzyme-linked immunosorbent assayJournal of Clinical Microbiology, 24
E. Tabor, J. Epstein (2002)
NAT screening of blood and plasma donations: evolution of technology and regulatory policy *Transfusion, 42
(1999)
Phase IV study of PLAS + SD : hepatitis A ( HAV ) and parvovirus B 19 safety results
J. Jordan, B. Tiangco, J. Kiss, W. Koch (1998)
Human Parvovirus B19: Prevalence of Viral DNA in Volunteer Blood Donors and Clinical Outcomes of Transfusion RecipientsVox Sanguinis, 75
M. Yunoki, M. Tsujikawa, T. Urayama, Y. Sasaki, M. Morita, H. Tanaka, S. Hattori, K. Takechi, K. Ikuta (2003)
Heat sensitivity of human parvovirus B19Vox Sanguinis, 84
Ulrike Koenigbauer, T. Eastlund, J. Day (2000)
Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent‐treated pooled plasmaTransfusion, 40
J. Saldanha, N. Lelie, M. Yu, A. Heath (2002)
Establishment of the first World Health Organization International Standard for human parvovirus B19 DNA nucleic acid amplification techniquesVox Sanguinis, 82
E. Santagostino, P. Mannucci, A. Gringeri, A. Azzi, M. Morfini, R. Musso, R. Santoro, M. Schiavoni (1997)
Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilizationTransfusion, 37
BACKGROUND: Parvovirus B19 (B19) is known to cause a variety of human diseases in susceptible individuals by close contact via the respiratory route or by transfusion of contaminated blood or blood products. In this study, whether a case of B19 transmission was causally related to the infusion of implicated lots of a solvent/detergent (S/D)‐treated, immunoaffinity‐purified factor VIII concentrate (antihemophilic factor (human)(AHF)) was investigated. STUDY DESIGN AND METHODS: Anti‐B19 (both immunoglobulin M (IgM) and immunoglobulin G (IgG)) and B19 DNA (by a nucleic acid testing (NAT) procedure) were assayed in two implicated product lots, a plasma pool, and a recipient's serum sample. Analysis of the partial B19 sequences obtained from sequencing clones or direct sequencing of the samples was performed. RESULTS: Only one of the two implicated lots was B19 DNA–positive. It contained 1.3 × 103 genome equivalents (geq or international units (IU)) per mL. The negative lot was derived from plasma screened for B19 DNA by NAT in a minipool format to exclude high‐titer donations, whereas the positive lot was mostly from unscreened plasma. This high‐purity AHF product had no detectable anti‐B19 IgG. A 4‐week postinfusion serum sample from a recipient, who received both lots and became ill, was positive for the presence of B19 antibodies (both IgM and IgG) as well as B19 DNA. The B19 sequences from the positive lot, its plasma pool, and the recipient's serum sample were closely related. CONCLUSION: These findings and the recipient's clinical history support a causal relationship between the implicated AHF product and B19 infection in this recipient. The seronegative patient became infected after receiving 2 × 104 IU (or geq) of B19 DNA, which was present in this S/D‐treated, high‐purity AHF product.
Transfusion – Wiley
Published: Jun 1, 2005
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.